Evidence map›Paper›PMID 34877075›Full record

ReviewDermatology practical & conceptual2021

Surgery for Cutaneous Squamous Cell Carcinoma and its Limits in Advanced Disease.

David Moreno-Ramírez, Francisca Silva-Clavería, Almudena Fernández-Orland, Noemí Eiris, Andrés Ruiz de Casas, Lara Férrandiz

Open access · diamondAbstract readReview
In one paragraph

Review in Dermatology practical & conceptual, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Managing Advanced Squamous Cell Carcinoma: A Guide for the Dermatology Clinician.The Journal of clinical and aesthetic dermatology · 2025
    Review
  6. Article
  7. Clinical and histopathological features of advanced cutaneous squamous cell carcinoma with varying responses to cemiplimab.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

David Moreno-RamírezDepartment of Medical-&-Surgical Dermatology. University Hospital Virgen Macarena. Medicine School, University of Sevilla. Seville, Spain.
Francisca Silva-ClaveríaDepartment of Medical-&-Surgical Dermatology. University Hospital Virgen Macarena. Medicine School, University of Sevilla. Seville, Spain.
Almudena Fernández-OrlandDepartment of Medical-&-Surgical Dermatology. University Hospital Virgen Macarena. Medicine School, University of Sevilla. Seville, Spain.
Noemí EirisDepartment of Medical-&-Surgical Dermatology. University Hospital Virgen Macarena. Medicine School, University of Sevilla. Seville, Spain.
Andrés Ruiz de CasasDepartment of Medical-&-Surgical Dermatology. University Hospital Virgen Macarena. Medicine School, University of Sevilla. Seville, Spain.
Lara FérrandizDepartment of Medical-&-Surgical Dermatology. University Hospital Virgen Macarena. Medicine School, University of Sevilla. Seville, Spain.
Hospital Universitario Virgen Macarena · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgery remains the first-line therapeutic option for most patients with cutaneous squamous cell carcinoma (cSCC). However, in the current therapeutic landscape, surgery must attempt to the complete tumor resection (R0 resection) with the lowest risk of surgical complications. This double aim is usually accomplished through standard excision with clinical margins in patients with low-risk tumors or by some of the micrographically controlled surgery procedures for patients with tumors at high-risk of local recurrence and metastasis. Surgery is also a first-line treatment for nodal metastases of cSCC as well as an option to consider in patients who develop recurrences while receiving immunotherapy, or as a palliation procedure in patients with advanced tumors. Neoadjuvant immunotherapy, that is the use of a medical treatment before surgery, is under investigation in patients with cSCC. The decision-making process and guidelines recommendations regarding cSCC surgery are reviewed in this manuscript.

Indexed as

cutaneous squamous cell carcinomaMohs surgerynodal metastasesnodal surgeryoncologic surgerysurgery

Identifiers

PMID34877075
PMCPMC8609953
OpenAlexW3204598582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.